久久久精品欧美一区二区三区,国产欧美久久久精品影院,亚洲AV福利天堂一区二区三亚洲欧洲日韩国产AⅤ在线,亚洲成av人在线视,四虎国产精品永久地址99自拍三区一级国产片,亚洲男人的天堂久久无在线观看免费黄视频,亚洲一级特黄大片在线播放,国产成人精品区在线观看

Gene Therapy
Home > Application > Gene Therapy > Adeno-Associated Virus

Adeno-Associated Virus

Adeno-associated virus (AAV) is the most commonly used vector in gene therapy, with a diameter of about 20 nm and no envelope. Its genome is about 4.8 kb in length. AAV does not encode DNA polymerase and relies on host cells or helper viruses to synthesize its own genome, so it cannot replicate autonomously. AAV is quite prevalent in humans and other primates, with 11 known serotypes. In addition, many artificial variants of AAV have been developed to improve the efficiency of AAV as vectors in clinical and research applications. For example, Glybera?, the world's first approved AAV-based product, uses AAV1 to deliver lipoprotein lipase (LPL) to treat patients with LPL deficiency. Luxturna? was approved in 2017 as an AAV2-based treatment for Leber's congenital amaukia, which causes progressive blindness, and Zolgensma? was approved in 2019 as an AAV9-based treatment for spinal muscular atrophy (SMA).

 

There are different platform strategies for the upstream production of AAV, including herpes simplex virus (HSV) infection, insect cell-baculovirus expression vector system, and stable production cell line, but the method based on transient transfection of HEK293 cell by plasmid DNA is currently the mainstream method for the production of clinical materials, which is more flexible and easy to use, with low up-front engineering effort, thus can help to quickly initiate the first-in-human studies. Typical process steps for the production of AAV based on transient transfection include: adherent or suspension culture based cell expansion, plasmid transfection, viral vector production, cell lysis, purification – including clarification, affinity capture chromatography, ion exchange polish chromatography, tangential flow filtration for concentration/diafiltration, final sterile filtration and fill/finish.

 

Adeno-Associated Virus

 

The choice of adherent vs. suspension culture should be comprehensively considered based on the technical capabilities of the platform, the stages, target indications and administration routes, and the expected demand for viral vectors. For large patient population , applications that require systemic administration or higher levels of viral vectors per dose, developing a production strategy based on suspension culture will be more conducive to ensuring the required scale-up capability, and it has been reported that AAV suspension culture production up to 2,000 L has been achieved. The purpose of upstream process development is to explore the optimal conditions for virus production, including improving transfection efficiency and ensuring its consistency under large-scale production conditions by adjusting transfection conditions, and intensifying virus productivity through strategies such as optimizing media formulations, maintain viral infectivity.

 

Although some AAV serotypes will partially secrete virus particles into the cell culture media during the culture process, in order to increase the yield of the virus, the downstream process of AAV starts with mechanical or chemical lysis of cells and DNA fragmentation under closed conditions, Subsequent clarification steps are designed to remove residual large amounts of plasmid DNA as well as host cell contaminants from cell lysis. Filter selection should consider the level of turbidity reduction, high product yield, and ease of scale-up. For the capture of AAV by affinity chromatography, there are currently specific affinity resin for various serotypes. Usually, a single-step affinity capture can achieve high purity. However, in order to ensure the specific level of impurity removal, ion exchange chromatography is generally used in combination as a polishing step. Especially for the challenge of separating empty and full capsids in AAV production, ion-exchange chromatography is currently the most commonly used method at production scale. Empty capsids are considered as in-process impurity by regulators and their percentage needs to be reduced as much as possible and the empty/full capsid ratio controlled to ensure consistency of gene therapy products. Tangential flow filtration aims to concentrate the product and replace it with a suitable buffer system. In view of the small particle size of AAV, MWCO 100kD membrane modules can be selected, while sterile filtration aims to reduce microbial load and meet the required sterility regulatory requirements.


Related Products
Contact Us
  • Tel.: +86 021 6434 0155
  • E-Mail: marketing@duoningbio.com
  • Address: Building 30, No. 1525 Minqiang Road, Songjiang District, Shanghai
Message

Copyright ? Shanghai Duoning Biotechnology Co., Ltd. All Rights Reserved Sitemap | Technical Support: Reanod

WeChat
WeChat

Message-

Duoning Biotechnology

+86 021 6434 0155

国产国产精品人在线视,| 亚洲熟女伦子伦av一区二区三区| 亚洲自慰白浆无码AV专区| 99久久国产综合精品五月天喷水| 国产精品视频综合区| 毛片a级毛片免费观看品善网| jlzz日本人年轻护士出水视频| 久久人妻少妇p| 国内精品久久久久影院蜜芽| 一区二区性生活观看玖玖资源站国产精品| 午夜福利视频集合1000 92| VIDEO日本老熟妇亚洲精品国产首次亮相| 国产AV无码专区亚洲精品| 亚洲va成无码人在线观看天堂| 国产在线观看一区精品| 无码h黄肉动漫在线观看999| 亚洲午夜福利国产门事件| 国产在线拍揄自揄拍视频| 国产午夜无码片在线观看网站日本| 第一亚洲中文久久精品无码| 国产办公室秘书无码精品99| 国产在线观看你懂的网址视频| 国产手机自在线视频| 手机看片久久国产永久免费| 69综合精品国产二区无码| 人妻无码不卡中文字幕系列| 国产精品视频免费看| 国产在线视频福利资源站| 普通话对白国产精品一级毛片| 国产自产视频在线观看香蕉| 国产香蕉97碰碰久久人人| 狠狠躁夜夜躁av网站中文字幕 | 国产黑客破解一区二区三区| 国产亚洲综合区成人国产系列| 一本久道久久综合狠狠爱| 大屁股av系列在线 哟男哟女视频八区 | 曰本一区二区视频在线观看| 国产AⅤ丝袜美腿丝袜视频| 久久午夜夜伦鲁鲁片无码免费| a级国产乱理论片在线观看| 日韩精品一区二区三区视频在线观看|